The Rutgers Cancer Institute of New Jersey prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated states in the nation. As a matrix and consortium cancer center that has been continuously funded by the NCI Cancer Center Support Grant (CCSG) mechanism since 1997, the Cancer Institute conducts state-of-the-art research, patient care, and outreach/education.
The Cancer Institute of New Jersey attracts investigators from a wide range of scientific disciplines to focus on cancer research.
Based on current research strengths and direction, members are now organized into five programs comprised of faculty who form cohesive, interdisciplinary groups supported by peer-reviewed grants and Cancer Institute of New Jersey shared resources. Programs are organized into three divisions: Basic Science, Clinical Science, and Public Health Science.
Cancer Metabolism and Growth
Program Leaders: Eileen White, PhD and Wei-Xing Zong, PhD
Genome Instability and Cancer Genetics
Program Leader: Zhiyuan Shen, MD, PhD and Chang S. Chan, PhD
Program Leaders: X. F. Steven Zheng, PhD and Joseph R. Bertino, MD
Clinical Investigations and Precision Therapeutics
Program Leaders: Howard L. Kaufman, MD, FACS and Shridar Ganesan, MD, PhD
Cancer Prevention and Control
Program Leaders: Elisa V. Bandera, MD, PhD and Sharon Manne, PhD
Rutgers Cancer Institute of New Jersey has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has statewide authority beyond the university matrix, thus establishing an environment to foster and formalize a vision of transdisciplinary and translational research.